RT-3 + Cagrilintide Blend

This research blend combines RT-3 (Retatrutide-type), a triple agonist at the GLP-1, GIP, and glucagon receptors, with Cagrilintide, a long-acting acylated amylin analogue that acts at amylin (AMY1/AMY3) and calcitonin receptors. Each vial holds 5mg of each compound, bringing incretin/glucagon signaling and amylin signaling together in a single research material. The individual compounds have each been studied extensively; the pairing of an amylin analogue with incretin-receptor agonism has been examined in the cagrilintide + semaglutide combination. This blend is utilized in laboratory research to study how these receptor systems interact. All discussion herein is limited to experimental research contexts and does not imply applied, therapeutic, or physiological use.

This RT-3/Cagrilintide blend is employed in laboratory research to study the interaction between incretin/glucagon receptor pathways and amylin receptor pathways. Common experimental applications include energy balance studies, food intake and satiety assays, body composition analyses, and glucose homeostasis assessments. Research protocols use this pairing to investigate whether adding amylin receptor agonism to multi-receptor incretin activity changes metabolic outcomes relative to either pathway alone.

Mechanistically, the two components engage separate receptor families. RT-3 acts through three class B G-protein coupled receptors: GLP-1R and GIPR provide glucose-dependent insulin secretion and appetite effects, while glucagon receptor activation contributes energy expenditure and hepatic lipid oxidation. Cagrilintide acts at amylin receptors, which are calcitonin receptors paired with receptor activity-modifying proteins (RAMPs), concentrated in hindbrain regions such as the area postrema. Amylin signaling reduces meal size, slows gastric emptying, and suppresses glucagon after meals, a pathway distinct from, and studied as complementary to, incretin signaling.

Cagrilintide was developed as a long-acting amylin analogue designed for once-weekly administration in clinical trials, and has been evaluated alone in a dose-finding phase 2 trial and in combination with the GLP-1 receptor agonist semaglutide. Retatrutide has been evaluated in phase 2 trials as a triple receptor agonist. Published data on retatrutide combined specifically with cagrilintide are limited; the rationale for the pairing rests on the separate literature for each pathway and on amylin + incretin combination studies. All findings are interpreted strictly within the context of laboratory research models.